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Anxiety and depression can contribute to these issues and should be managed as in other women.
HORMONE REPLACEMENT THERAPY IN BREAST CANCER SURVIVORS
Two large trials (HABITS and Stockholm) reported inconsistent findings related to the use of systemic HRT after breast cancer. The HABITS trial reported a threefold increase in the risk of new primary or recurrent breast cancers, while the Stockholm trial found no increased recurrence risk after 4 years of therapy. [2] [3] [4] Debate exists over whether the difference in outcome was due to the different therapy regimens used, or chance. Regardless, the use of systemic oestrogen is not recommended in breast cancer survivors. [2] [3] [4] The LIBERATE trial studied the use of tibolone to manage menopausal symptoms and showed an increased risk of recurrence within the intervention group. However, the study lacked the power to assess tibolone alone (without aromatase inhibitors) on risk of breast cancer recurrence. 5 Other hormonal preparations such as progestins and androgens may play a role in managing menopausal symptoms, but require further investigation. 6 
NON-HORMONAL THERAPIES
Lifestyle can impact not only on menopausal symptoms, but also risk of cancer recurrence, general health, all cause mortality, and wellbeing. Maintaining a healthy body mass index (BMI), ceasing smoking, limiting alcohol intake, and exercising regularly can moderate flushes, may reduce the risk of osteoporosis, can provide relief from arthralgia, and may also directly reduce the risk of breast cancer recurrence.
What are the evidence-based options (hormonal and nonhormonal) for the management of menopausal symptoms in breast cancer survivors?
Many symptoms will improve in time, without intervention. Hot flushes tend to improve over time in post-menopausal women not taking endocrine therapy and many clinical trials have demonstrated a large placebo effect (up to 70%) with interventions for menopausal symptoms. 8 Symptoms related to endocrine therapy tend to stabilise after 3 months of therapy so women experiencing menopausal symptoms after starting endocrine therapy should be encouraged to persevere with therapy, perhaps with a short treatment holiday.
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Selective serotonin reuptake inhibitors (SSRIs) and selective noradrenaline reuptake inhibitors (SNRIs) may reduce the severity and frequency of hot flushes, but side effects of dry mouth, headache, nausea, and insomnia may be experienced. 6 Some SSRIs interfere with tamoxifen therapy, and therefore venlafaxine and desvenlafaxine are preferred options for these women. 12 Gabapentin and clonidine have been shown to reduce menopausal hot flushes in breast cancer patients, although both have potential side effects. 8 Cognitive impairment is a common symptom experienced by the survivors of breast cancer treated with adjuvant therapies (particularly chemotherapy) and this effect may be exaggerated during treatment induced menopause. 6 One study has shown that modafinil (an antiepileptic) improved cognitive performance in survivors of breast cancer.
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COMPLEMENTARY THERAPIES
Evidence is lacking to support the use of alternative therapies to manage menopausal symptoms in women with a history of breast cancer. However, paced respiration, hypnotherapy, and acupuncture have demonstrated some beneficial effects. 1, 8 Black cohosh is believed to produce significant reduction in hot flushes, yet evidence is lacking and concerns exist following reports of liver failure. 1 To support bone mineral density (BMD), supplementation of vitamin D (which may also reduce bone pain) and calcium are important; Tai Chi and vibration exercises have also been shown to increase BMD. 13 Group cognitive behavioural therapy may also have a role.
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CONCLUSION
Menopausal symptoms are common in women after breast cancer treatment and these can significantly impact on quality of life and compliance with therapy. In most cases, HRT is not recommended, however a range of other management options is available to improve menopausal symptoms in breast cancer survivors (see Box 1).
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